

Supplementary Information

Relative efficacy of checkpoint inhibitors for advanced NSCLC according to programmed death-ligand-1 expression: a systematic review and network meta-analysis.

Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Joo Han Lim.

Supplementary Figure S1. Risk of bias of included studies

Supplementary Table S1. Relative effects in pooled hazard ratios and 95% credible intervals by PD-L1 expression level

Supplementary Table S2. Relative effects in pooled hazard ratios and 95% credible intervals by PD-L1 expression level in second-or later-line settings

Supplementary Table S3. Rank probability in second- or later-line settings

Supplementary Figure S1. Risk of bias of included studies

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
CheckMate017	?	?	-	?	+	+	+
CheckMate026	?	?	-	+	+	+	+
CheckMate057	?	?	-	?	+	+	+
Keynote010	+	+	-	+	+	+	+
Keynote024	?	?	-	+	+	+	+
OAK	+	+	-	?	+	+	+
POPLAR	+	+	-	+	+	+	+

Supplementary Table S1. Relative effects in pooled hazard ratios and 95% credible intervals by PD-L1 expression level

A. PD-L1 < 1%

Chemotherapy	0.77 (0.63-0.96)	0.79 (0.63-1.00)
	Atezolizumab	1.02 (0.74-1.42)
		Nivolumab

B. PD-L1 1-49%

Chemotherapy	0.83 (0.67-1.05)	0.95 (0.79-1.15)	0.76 (0.64-0.90)
	Atezolizumab	1.14 (0.84-1.54)	0.91 (0.69-1.20)
		Nivolumab	0.80 (0.62-1.04)
			Pembrolizumab

C. PD-L1 ≥ 50%

Chemotherapy	0.42 (0.29-0.61)	0.63 (0.48-0.83)	0.55 (0.46-0.66)
	Atezolizumab	1.52 (0.95-2.40)	1.31 (0.87-1.97)
		Nivolumab	0.87 (0.63-1.20)
			Pembrolizumab

Each cell represents the effect of the column-defining intervention relative to the row-defining intervention. Effect estimates are presented as hazard ratios and 95% credible intervals are in parentheses.

Supplementary Table S2. Relative effects in pooled hazard ratios and 95% credible intervals by PD-L1 expression level in second-or later-line settings

A. PD-L1 < 1%

Chemotherapy	0.77 (0.63-0.96)	0.79 (0.63-1.00)
	Atezolizumab	1.02 (0.74-1.42)
		Nivolumab

B. PD-L1 1-49%

Chemotherapy	0.83 (0.67-1.05)	0.76 (0.59-1.00)	0.76 (0.64-0.90)
	Atezolizumab	0.92 (0.64-1.30)	0.91 (0.69-1.20)
		Nivolumab	1.00 (0.73-1.37)
			Pembrolizumab

C. PD-L1 ≥ 50%

Chemotherapy	0.42 (0.29-0.61)	0.40 (0.27-0.61)	0.51 (0.41-0.64)
	Atezolizumab	0.96 (0.55-1.66)	1.22 (0.79-1.87)
		Nivolumab	1.27 (0.80- 2.04)
			Pembrolizumab

Each cell represents the effect of the column-defining intervention relative to the row-defining intervention. Effect estimates are presented as hazard ratios and 95% credible intervals are in parentheses.

Supplementary Table S3. Rank probability in second- or later-line settings

A. PD-L1 < 1%

	Rank 1	Rank 2	Rank 3
Atezolizumab	0.55	0.44	0.01
Nivolumab	0.45	0.52	0.03
Chemotherapy	0	0.04	0.96

B. PD-L1 1-49%

	Rank 1	Rank 2	Rank 3	Rank 4
Atezolizumab	0.15	0.28	0.51	0.06
Nivolumab	0.43	0.31	0.24	0.02
Pembrolizumab	0.42	0.41	0.17	0
Chemotherapy	0	0	0.08	0.92

C. PD-L1 ≥ 50%

	Rank 1	Rank 2	Rank 3	Rank 4
Atezolizumab	0.42	0.42	0.16	0
Nivolumab	0.53	0.33	0.13	0
Pembrolizumab	0.05	0.25	0.71	0
Chemotherapy	0	0	0	1

Each cell represents the effect of the column-defining intervention relative to the row-defining intervention. Effect estimates are presented as hazard ratios and 95% credible intervals are in parentheses.